luteal phase. Other specified conditions associated with female genital organs and menstrual cycle
Conditions
Interventions
Intervention 1: control group : received cyclogest vaginal suppository twice a day for luteal phase support. Intervention 2: intervention group 1: patients who received didrogesteron oral tablet 10mg
Treatment - Drugs
control group : received cyclogest vaginal suppository twice a day for luteal phase support
intervention group 1: patients who received didrogesteron oral tablet 10mg twice a day.
intervention group2: patients who received didrogesteron oral tablet 10mg twice a day in combination with 3 dose of Amp Dipherelin 0.1mg in days of embryo transfer,(3 day,6 day )
intervention group3: patients who received didrogesteron oral tablet 10mg twice a day in combination with 3 dose of Amp HCG 1500u in days of embryo transfer,(3 day,6 day)
Sponsors
Vice chancellor for research of Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: inclusion criteria: unexplained infertility ? tubal factor? mild male factor ? POF ? sub fertility in pco field ? average age between 20-40? normal uterine cavity exclusion criteria: women over 40 year? endometriosis stage III ?IV? Hydro salpinx ? severe male factor? ab normal uterine cavity ? failed embryo transfer cycle =3
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical pregnancy rate. Timepoint: 6 week gestation. Method of measurement: vaginal sonogeraphy trans. | — |
Secondary
| Measure | Time frame |
|---|---|
| Ongoing pregnancy rate,Abortion rate. Timepoint: 12 week gestation. Method of measurement: vaginal sonogeraphy trans. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr parastoo soheil
Shiraz University of Medical Sciences
Outcome results
None listed